NCT00923026Enrolling by invitation
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA. Eligibility: Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol Design Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 1150 (estimated)
- First submitted
- 17 Jun 2009
- Start date
- 15 Jun 2009
- Lead sponsor
- National Cancer Institute (NCI)
- Diseases
- Neuroendocrine tumours, Melanoma
- NCT number
- NCT00923026
What you commit to
- Study type: Observational
- Planned participants: 1150
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.
Criteria the registry did not label
- INCLUSION CRITERIA:
- Age greater than or equal to 18 years.
- Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).
- For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institutes of Health Clinical Center Coordinator of this site? Confirm its status | Bethesda | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.